The Positive results from the EMERALD-1 Phase III trial showed AstraZeneca?s IMFINZI®(durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization.These results will be presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California. Approximately 20-30% of patients with HCC, the most common type of liver cancer, are eligible for embolization, a procedure that blocks the blood supply to the tumor and can also deliver chemotherapy or radiation therapy directly to the liver. Despite being the standard of care in this setting, most patients who receive embolization experience disease progression or recurrence within eight months.